Every round on record, with the sources behind each and the investors on them.
A biotechnology company advancing complement-powered immune engagers
commitbio.comCopenhagen and AarhusBiotechFounded 2021
16 sources · checked 2 times, last 2d ago
Developing: it holds up against its sources so far, and firms up as more reporting lands.
The company release calls this a $60 million seed financing, but European Biotechnology says earlier seed financings brought total seed funding to €21.5 million and the final closing brought the total to $60 million; the new money in this close is not stated.
| Round | Amount | Announced | Lead | Buzz |
|---|---|---|---|---|
| Seed | $60M financing total | 2026-11-17 | Ackermans & van Haaren | 11 outlets. #88 in Trending |
16 sources · checked 2 times, last 2d ago [ DEVELOPING ] Developing: it holds up against its sources so far, and firms up as more reporting lands. read against 4 of 16 sources
The company release calls this a $60 million seed financing, but European Biotechnology says earlier seed financings brought total seed funding to €21.5 million and the final closing brought the total to $60 million; the new money in this close is not stated. | ||||
Commit Biologics is a Danish biotech developing complement-powered immune engagers—engineered antibodies that recruit C1q to selectively eliminate diseased cells—for oncology and autoimmune diseases.
Commit is trying to address limitations of T-cell-focused immunotherapies—including dependence on functional T cells, poor tumor or tissue infiltration, exhaustion and immune-related toxicities—by directing the abundant complement system to diseased cells through its BiCE platform. Its latest $60 million seed financing is intended to take first development candidate COM002 into the clinic, advance a second program into IND-enabling development and expand the platform pipeline.
Checked against 14 sources 2d ago
Also named as backers in company research: BioInnovation Institute, Innovation Fund Denmark